No, I had a virus at onset.
No, I had a virus at onset.
Or I could get whole exome testing done, which is down to US$400 now
I'm actually a bit furious that the urine testing was only for a single SNP
http://forums.phoenixrising.me/index.php?threads/new-exome-testing-400.48137/@Valentijn btw how do you get direct-to-consumer exome sequencing for $400? I know I've read about it but can't find now.
Did your mitochondrial clinician give you a reason for why he/she was ruling out MELAS despite your elevated alanine and lactate levels?
The negative result for 3243 in the genetic urine test, and my height and weight not being below average. Also that my lactate didn't get sky high from walking up and down the stairs, and he didn't seem to be interested in it staying high for at least 6 hours afterward.
According to their website, it tests for the most common MELAS mutation, 3243. It indicates how much of the mutated form is present compared to the non-mutated form, so I expect it's primarily used in research to track progression or remission in response to interventions. Since it's the most common, it's pretty much the only mutation used in research.Would you explain to me what is the genetic urine test?
That translates to "mitochondrial DNA: fully reviewed, no mutations found". Perhaps the test was fully reviewed, but the mitochondrial DNA was not. And it seems deliberately misleading to phrase it as "no mutations found" when "mutation not found" would be more accurate for a test of a single mutation.mDNA: geheel beoordeeld, geen mutaties gevonden
Habitual Physical Activity in Mitochondrial Disease
Shehnaz Apabhai , Grainne S. Gorman , Laura Sutton, Joanna L. Elson, Thomas Plötz, Douglass M. Turnbull, Michael I. Trenell
![]()
Abstract
- Published: July 22, 2011
- https://doi.org/10.1371/journal.pone.0022294
Purpose
Mitochondrial disease is the most common neuromuscular disease and has a profound impact upon daily life, disease and longevity. Exercise therapy has been shown to improve mitochondrial function in patients with mitochondrial disease. However, no information exists about the level of habitual physical activity of people with mitochondrial disease and its relationship with clinical phenotype.
Methods
Habitual physical activity, genotype and clinical presentations were assessed in 100 patients with mitochondrial disease. Comparisons were made with a control group individually matched by age, gender and BMI.
Results
Patients with mitochondrial disease had significantly lower levels of physical activity in comparison to matched people without mitochondrial disease (steps/day; 6883±3944 vs. 9924±4088, p = 0.001). 78% of the mitochondrial disease cohort did not achieve 10,000 steps per day and 48%were classified as overweight or obese. Mitochondrial disease was associated with less breaks in sedentary activity (Sedentary to Active Transitions, % per day; 13±0.03 vs. 14±0.03, p = 0.001) and an increase in sedentary bout duration (bout lengths / fraction of total sedentary time; 0.206±0.044 vs. 0.187±0.026, p = 0.001). After adjusting for covariates, higher physical activity was moderately associated with lower clinical disease burden (steps / day; rs = −0.49; 95% CI −0.33, −0.63, P<0.01). There were no systematic differences in physical activity between different genotypes mitochondrial disease.
Conclusions
These results demonstrate for the first time that low levels of physical activity are prominent in mitochondrial disease. Combined with a high prevalence of obesity, physical activity may constitute a significant and potentially modifiable risk factor in mitochondrial disease.
Twenty-eight per cent of the mitochondrial disease group were overweight (BMI 25–29.9 kg/m2) and 20% were obese (BMI ≥30 kg/m2); only 4% were underweight (BMI<18.5 kg/m2).
MELAS: A nationwide prospective cohort study of 96 patients in Japan
Shuichi Yatsuga, Nataliya Povalko, Junko Nishioka, Koju Katayama, Noriko Kakimoto, Toyojiro Matsuishi, Tatsuyuki Kakuma, Yasutoshi Koga
and Taro Matsuoka for MELAS Study Group in Japan
ABSTRACT
Background: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (OMIM 540000) is the most dominant subtype of mitochondrial myopathy. The aim of this study was to determine the prevalence, natural course, and severity of MELAS.
Methods:
A prospective cohort study of 96 Japanese patients with MELAS was followed between June 2003 and April 2008. Patients with MELAS were identified and enrolled based on questionnaires administered to neurologists in Japan. MELAS was defined using the Japanese diagnostic criteria for MELAS. Two follow-up questionnaires were administered to neurologists managing MELAS patients at an interval of 5 years.
Results:
A prevalence of at least 0.58 (95% confidential interval (CI), 0.54–0.62)/100,000 was calculated for mitochondrial myopathy, whereas the prevalence of MELAS was 0.18 (95%CI, 0.02–0.34)/100,000 in the total population. MELAS patients were divided into two sub-groups: juvenile form and adult form. Stroke-like episodes, seizure and headache were the most frequent symptoms seen in both forms of MELAS. Short stature was significantly more frequent in the juvenile form, whereas hearing loss, cortical blindness and diabetes mellitus were significantly more frequent in the adult form. According to the Japanese mitochondrial disease rating scale, MELAS patients showed rapidly increasing scores (mean±standard deviation, 12.8±8.7) within 5 years from onset of the disease. According to a Kaplan–Meier analysis, the juvenile form was associated with a higher risk of death than the adult form (hazard ratio, 3.29; 95%CI, 1.32–8.20;p=0.0105).
Conclusions and General Significance:
We confirmed that MELAS shows a rapid degenerative progression within a 5-year interval and that this occurs in both the juvenile and the adult forms of MELAS and follows different natural courses. This article is part of a Special Issue entitled: Biochemistry of Mitochondria
I had my followup appointment over a month ago, and I fear that I'm getting a bit of a brush off, considering the circumstances.
The mitochondrial clinician also seems to think that being of normal height (for an American, not a Dutchie) makes MELAS very unlikely, and that MELAS patients are typically underweight, not overweight. But research of adult mixed mitochondrial disease patients showed half were overweight, so I think he was making some inappropriate assumptions based on how MELAS presents in infancy or early childhood, versus in adults.
So he's saying MELAS is ruled out, and won't recommend a muscle biopsy and genetic test of it, but due to the alanine and fatty acids being elevated, he's ordered CPT2 genetic testing (blood) for a possible carnitine deficiency.
I also had elevated alanine in a blood amino acid test. In a urine test I had elevated unmetabolized fatty acids and they recommended vitamin B2 and carnitine.
Do you know how high alanine levels relate to alanine transaminase activity (ALT)? I guess high ALT activity would cause high alanine by conversion from glutamate+pyruvate? I just don't read it anywhere explicitly and am unsure because the enzyme goes in both directions..
CPT2 has been ruled out now, and the doctor has already said he has no further recommendations for any other investigations. So that's it as far as the Dutch system is concerned, unless I can find another angle to start over from.Your lab tests could lead on to other tests and so on. For this reason I would not aim to do these privately unless it's necessary. The carnitine deficiency they mention is useful because there are several conditions which can lead to secondary carnitine deficiency. Some say MELAS does but others (such as researcher Tarnopolsky) don't agree.
CPT2 has been ruled out now, and the doctor has already said he has no further recommendations for any other investigations. So that's it as far as the Dutch system is concerned, unless I can find another angle to start over from.
I don't think carnitine was measured directly, since it wasn't mentioned as an abnormal result. So he was probably just going off of the raised alanine and certain fatty acids. This is why I need to see my full resultsCPT2 is just one of many conditions which can cause carnitine deficiency. If your doc was testing for CPT2 then presumably they have established a carnitine deficiency exists. There are many other important conditions other than CPT2 (such as my own PA/MMA) in which carnitine becomes severely depleted.
Just came across this link about MELAS
http://discovery.ucl.ac.uk/135344/1/135344_MELAS Final Draf.pdf